This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schroeder, S. J.
Right arrow Articles by Moore, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schroeder, S. J.
Right arrow Articles by Moore, P. B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2007, p. 4462-4465, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00455-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Negamycin Binds to the Wall of the Nascent Chain Exit Tunnel of the 50S Ribosomal Subunit{triangledown}

Susan J. Schroeder,1,{dagger},{ddagger} Gregor Blaha,2,3,{dagger} and Peter B. Moore1,2*

Department of Chemistry, Yale University, New Haven, Connecticut 06520-8107,1 Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520-8024,2 Howard Hughes Medical Institute, New Haven, Connecticut 06520-81143

Received 3 April 2007/ Returned for modification 15 June 2007/ Accepted 24 July 2007


arrow
ABSTRACT
 
Negamycin, a small-molecule inhibitor of protein synthesis, binds the Haloarcula marismortui 50S ribosomal subunit at a single site formed by highly conserved RNA nucleotides near the cytosolic end of the nascent chain exit tunnel. The mechanism of antibiotic action and the function of this unexplored tunnel region remain intriguingly elusive.


arrow
TEXT
 
Negamycin is a translation inhibitor that prevents the release of complete proteins from the ribosome and thus causes an accumulation of polysomes. Negamycin also induces miscoding (1, 15, 23, 26) but does not interfere with peptide initiation or elongation (7, 25, 28). Because the inhibition of peptide release and miscoding vary independently in negamycin derivatives (27), negamycin may interfere with ribosome function in two distinct ways. Here we report the results of crystallographic experiments which show that negamycin binds to the wall of the peptide exit tunnel of the large ribosomal subunit. This interaction may account for negamycin's inhibition of peptide release.

The 50S ribosomal subunits were prepared from wild-type Haloarcula marismortui cells and crystallized as described previously (3). Negamycin was soaked into the crystals following previously described protocols (11, 16, 20, 21). Five millimolar negamycin is approximately five times the MIC of negamycin for this organism. Crystals were equilibrated at least twice with solutions containing 5 mM negamycin dissolved in buffer B (12% [wt/vol] polyethylene glycol 6000, 20% [vol/vol] ethylene glycol, 1.7 M NaCl, 0.5 M NH4Cl, 1 mM CdCl2, 100 mM potassium acetate, 6.5 mM acetic acid [pH 6.0], 30 mM MgCl2 or 100 mM SrCl2, 5 mM ß-mercaptoethanol) at 4°C over the course of 1 to 4 h, during which SrCl2 was included in soak solutions, and over 16 to 24 h, during which MgCl2 was included in soak solutions.

Data collected at the Advanced Light Source (ALS), using beamline 8.2.2, were processed as previously described (3). Unbiased-difference electron density maps were computed for each drug-ribosome complex, using as amplitudes [|Fo(hkl)|drug/ribosome – |Fo(hkl)|best native], where the |Fo(hkl)|s are measured amplitudes of the (hkl) reflection in the data collected from the two crystals whose structures were being compared, and phases obtained by rigid-body refinement of the native structure (Protein Data Bank code 1S72; 12) into the drug-ribosome data set. Structure refinements were done with CNS software (4) and included rigid-body, energy minimization, and B-factor refinement. In the final rounds of refinement, only those atoms within a 25- to 35-Å-diameter sphere centered on the antibiotic binding site were allowed to vary in position. The coordinates and structure factors for the negamycin complex described here may be found in the Protein Data Bank (code 2QEX; http://www.rcsb.org/pdb/home/home.do).

The functional significance of the negamycin binding site identified in the crystal structure was investigated by site-directed mutagenesis and random targeted mutagenesis and by the selection of naturally occurring mutations in Escherichia coli, and Thermus thermophilus. A pUC derivative was created containing a fragment of the E. coli rrnB cistron obtained from pLK35 between restriction sites for SphI and XbaI. It includes all of domain 1 and part of domain 2 of the 23S rRNA. Site-directed mutations were introduced into the pUC construct using a QuikChange kit (Stratagene) and following the manufacturer's protocol. Random mutations were introduced using error-prone PCR (5). These mutated DNA fragments were used to replace the corresponding sequences in pLK35, and the resulting plasmids were transformed into E. coli POP2136, which carries a temperature-sensitive {lambda} repressor. Mutated plasmids were propagated at 30°C and assayed for viability and negamycin sensitivity at 42°C. Mutant pLK35 plasmids were also transformed into the Squires strain SQZ10 or SZ7, and sucrose selection was used to exchange the mutated plasmids for the plasmid carrying the single wild-type rRNA cistron on which these strains depend for survival (2; S. Qwan, personal communications).

Selections for naturally occurring mutations were performed with the E. coli Squires strains SQZ10 and SZ7 at 25 µg/ml negamycin, which is twice the MIC, and with T. thermophilus strains HB8 and IB21 at 100 µg/ml or 200 µg/ml negamycin or using 250 µg disks under growth conditions that were otherwise standard for both organisms (2, 10; S. Qwan, personal communication). The MIC of negamycin for H. marismortui was measured in liquid culture and proved to be so high that resistance mutations could not be selected in H. marismortui because the amount of drug available was too small.

Difference electron density maps computed using data obtained from two different crystals at resolutions of around 3 Å show a single positive feature large enough to accommodate the drug. These maps indicate that the drug binds to a cleft in the wall of the polypeptide exit tunnel, close to its cytosolic end, in an extended conformation (Fig. 1A; Table 1). However, the maps' resolutions are not high enough to determine the orientation of the drug in its binding site unambiguously. The orientation shown here was chosen because it maximizes the number of hydrogen bonds the drug forms with the ribosome and avoids electrostatic repulsions (Fig. 1D). It is also consistent with structure-activity relationship studies, which show the importance of the hydroxyl group, the stereochemistry at position 3, and both termini of negamycin for its activity (12, 13, 17-19, 27). The drug interacts primarily with RNA backbone atoms. The N1 and N4 amino groups of the drug hydrogen bond to the nonbridging phosphate oxygens of HmG518(Ec512) and HmU517(Ec511) (where Hm and Ec refer to H. marismortui and E. coli, respectively, the letter after "Hm" identifies the nucleotide type, and the number after "Hm" is the position of that nucleotide in the Hm 23S RNA sequence and the number in parenthesis is the corresponding sequence number in Ec), and its O4 and N3 atoms interact with a cation, possibly a magnesium ion, that has two ribosomal ligands, the O2P oxygen of HmU517(Ec511) and the N7 of HmG518(Ec512).


Figure 1
View larger version (49K):
[in this window]
[in a new window]

  		FIG. 1. (A) The position of the negamycin bound in the peptide exit tunnel. Negamycin, in yellow, is displayed on one half of the large subunit, which is shown sliced along the lumen of the peptide exit tunnel. The ribosomal proteins are displayed in blue, rRNAs in gray, and a modeled P site tRNA in orange. (B) Difference electron density map for negamycin contoured at 4 sigma. (C) Chemical structure of negamycin. (D) Interactions of negamycin with rRNA and a metal ion (green) at the binding site in the peptide tunnel.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Crystallographic statistics

The inhibitor binds to the irregularly structured region in domain 1 of the 23S rRNA that connects helices 24 and 2 [HmA509(Ec503)-HmG512(Ec506); and HmC515(Ec509)-HmG518(Ec512)]. The sequence in this region is >99% conserved across all species (6, 22), consistent with negamycin's lack of species specificity and also consistent with the hypothesis that this region is functionally significant. However, its function is unknown. These nucleotides are unreactive in chemical modification experiments (8), and no mutations have been reported in this region (24). However, low-resolution cryoelectron microscopy images suggest that this part of the 23S rRNA could be dynamic (7, 14).

To test the significance of the site, E. coli mutant strains were prepared in which EcG512(Hm518) was changed to U or deleted. Both strains retained sensitivity to negamycin, even though EcG512 is an important component of its binding site. Deletion of either Ec510-512 or Ec508 (Hm516-518 or Hm512) provided no insight because both were dominant lethal mutations. Finally, no rRNA mutations that conferred negamycin resistance emerged from selection experiments carried out using a single-operon strain of E. coli (2) or the HB9 and I21 strains of T. thermophilus (10). Finally, we note that the lumen of the tunnel is so large in the region where the drug binds that its binding should not interfere sterically with the passage of nascent polypeptides down the tunnel. Thus, further work will have to be done to determine the functional significance of the negamycin binding site reported here and to elucidate the mechanism of action of negamycin.


arrow
ACKNOWLEDGMENTS
 
We thank Ryoichi Matsuda of the University of Tokyo for providing the negamycin sample that made this study possible. We thank Catherine Squires for making the single ribosomal cistron strains SZ7 and SQZ10 of E. coli available to us and Albert Dahlberg and Stephen Gregory for giving us the HB8 and HB21 strains of Thermus thermophilus, the POP strain of E. coli, and the plasmid pLK35. We also thank the ALS staff for beamline 8.2.2. We thank Laryssa Vasylenko for ribosome preparation.

This work was supported by grants from the National Institutes of Health (PO1-GM022778 to P.B.M. and F32-GM067354 to S.J.S.).


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: 225 Prospect Street, P.O. Box 208107, New Haven, CT 06520-8107. Phone: (203) 432-3995. Fax: (203) 432-5781. E-mail: peter.moore{at}yale.edu Back

{triangledown} Published ahead of print on 30 July 2007. Back

{dagger} These two authors contributed equally to this work. Back

{ddagger} Present address: Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019-3051. Back


arrow
REFERENCES
 
    1
  1. Arakawa, M., M. Shiozuka, Y. Nakayama, T. Hara, M. Hamada, S. Kondo, D. Ikeda, Y. Takahashi, R. Sawa, Y. Nonomura, K. Sheykholeslami, K. Kondo, K. Kaga, T. Kitamura, Y. Suzuki, S. Takeda, and R. Matsuda. 2003. Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice. J. Antibiot. 134:751-758.
    2. 2
  2. Asai, T., T. D. Zaporojets, C. Squires, and C. L. Squires. 1999. Construction and initial characterization of Escherichia coli strains with few or no intact chromosomal rRNA operons. Proc. Natl. Acad. Sci. USA 96:1971-1976.[Abstract/Free Full Text]
    3. 3
  3. Ban, N., P. Nissen, J. Hanson, P. B. Moore, and T. A. Steitz. 2000. The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution. Science 289:905-920.[Abstract/Free Full Text]
    4. 4
  4. Brunger, A. T., P. D. Adams, G. M. Clore, W. L. DeLano, P. Gros, R. Grosse-Kunstleve, J.-S. Jiang, J. Kuszewski, M. Nilges, N. S. Pannu, R. J. Read, L. M. Rice, T. Simonson, and G. L. Warren. 1998. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 54:905-921.[CrossRef][Medline]
    5. 5
  5. Cadwell, R. C., and G. F. Joyce. 1992. Randomization of genes by PCR mutagenesis. PCR Methods Appl. 2:28-33.[Medline]
    6. 6
  6. Cannone, J. J., S. Subramanian, M. N. Schnare, J. R. Collett, L. M. D'Souza, Y. Du, B. Feng, N. Lin, L. V. Madabusi, K. M. Muller, N. Pande, Z. Shang, N. Yu, and R. R. Gutell. 2002. The comparative RNA web (CRW) site: an online database of comparative sequence and structure information for ribosomal, intron, and other RNAs. BMC Bioinformatics 3:2.[CrossRef][Medline]
    7. 7
  7. Corchuelo, M. C., A. Herzog, L. Desmarez, R. Lavalle, and A. Bollen. 1981. Resistance to the peptide-like antibiotic negamycin in Escherichia coli. Biochem. Biophys. Res. Commun. 100:1497-1503.[CrossRef][Medline]
    8. 8
  8. Gabashvilli, I. S., S. T. Gregory, M. Valle, R. Grassucci, M. Worbs, M. C. Wahl, A. E. Dahlberg, and J. Frank. 2001. The polypeptide tunnel system in the ribosome and its gating in erythromycin resistance mutants of L4 and L22. Mol. Cell. 8:181-188.[CrossRef][Medline]
    9. 9
  9. Reference deleted.
    10. 10
  10. Gregory, S. T., J. F. Carr, D. Rodriguez-Correa, and A. E. Dahlberg. 2005. Mutational analysis of 16S and 23S rRNA genes of Thermus thermophilus. J. Bacteriol. 187:4804-4812.[Abstract/Free Full Text]
    11. 11
  11. Hansen, J., P. B. Moore, and T. A. Steitz. 2003. Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. J. Mol. Biol. 330:1061-1075.[CrossRef][Medline]
    12. 12
  12. Klein, D. J., P. B. Moore, and T. A. Steitz. 2004. The roles of ribosomal proteins in the structure assembly, and evolution of the large ribosomal subunit. J. Mol. Biol. 340:141-177.[CrossRef][Medline]
    13. 13
  13. Kondo, S., K. Inuma, K. Yoshida, K. Yokose, Y. Ikeda, M. Shimazaki, and H. Umezawa. 1976. Syntheses and properties of negamycin analogs modified the delta-hydroxy-beta-lysine moiety. J. Antibiot. 29:208-211.[Medline]
    14. 14
  14. Mitra, K., C. Schaffitzel, F. Fabiola, M. S. Chapman, N. Ban, and J. Frank. 2006. Elongation arrest by SecM via a cascade of ribosomal RNA rearrangements. Mol. Cell 22:533-543.[CrossRef][Medline]
    15. 15
  15. Mizuno, S., K. Nitta, and H. Umezawa. 1970. Mechanism of action of negamycin in Escherichia coli K12. II. Miscoding activity in polypeptide synthesis directed by synthetic polynucleotide. J. Antibiot. 23:589-594.[Medline]
    16. 16
  16. Nissen, P., J. Hanson, N. Ban, P. B. Moore, and T. A. Steitz. 2000. The structural basis of ribosome activity in peptide bond synthesis. Science 289:920-930.[Abstract/Free Full Text]
    17. 17
  17. Pasquet, G., D. Boucherot, and W. R. Pilgrim. 1980. Synthesis of (±)-negamycin and of (±)-epinegamycin. Tetrahedron Lett. 21:931-934.[CrossRef]
    18. 18
  18. Raju, B., K. Mortell, S. Anandan, H. O'Dowd, H. Gao, M. Gomez, C. Hackbarth, C. Wu, W. Wang, Z. Yuan, R. White, J. Trias, and D. V. Patel. 2003. N- and C-terminal modifications of negamycin. Bioorg. Med. Chem. Lett. 13:2413-2418.[CrossRef][Medline]
    19. 19
  19. Raju, B., S. Anandan, S. Gu, P. Herradura, H. O'Dowd, B. Kim, M. Gomez, C. Hackbarth, C. Wu, W. Wang, Z. Yuan, R. White, J. Trias, and D. V. Patel. 2004. Conformationally restricted analogs of deoxynegamycin. Bioorg. Med. Chem. Lett. 14:3103-3107.[CrossRef][Medline]
    20. 20
  20. Schmeing, T. M., K. S. Huang, S. A. Strobel, and T. A. Steitz. 2005. An induced-fit mechanism to promote peptide bond formation and exclude hydrolysis of peptidyl-tRNA. Nature 438:520-524.[CrossRef][Medline]
    21. 21
  21. Schroeder, S. J., G. Blaha, J. Tirado-Rives, T. A. Steitz, and P. B. Moore. 2007. The structures of antibiotics bound to the E-site region of the 50S ribosomal subunit of Haloarcula marismortui: 13-deoxytedanolide and girodazole. J. Mol. Biol. 367:1471-1479.[CrossRef][Medline]
    22. 22
  22. Schuwirth, B. S., M. A. Borovinskaya, C. W. Hau, W. Zhang, A. Vila-Sanjuro, J. Holton, and J. H. Doudna-Cate. 2005. Structures of the bacterial ribosome at 3.5 Å resolution. Science 310:827-834.[Abstract/Free Full Text]
    23. 23
  23. Sutcliffe, J. 2005. Improving on nature: antibiotics that target the ribosome. Curr. Opin. Mircrobiol. 8:534-542.[CrossRef]
    24. 24
  24. Triman, K. L., A. Peister, and R. A. Goel. 1998. Expanded versions of the 16S and 23S ribosomal RNA mutation databases. Nucleic Acids Res. 26:280-284.[Abstract/Free Full Text]
    25. 25
  25. Uehara, Y., M. Hori, and H. Umezawa. 1976. Specific inhibition of the termination process of protein synthesis by negamycin. Biochim. Biophys. Acta 442:251-262.[Medline]
    26. 26
  26. Uehara, Y., S. Kondo, H. Umezawa, K. Suzukake, and M. Hori. 1972. Negamycin, a miscoding antibiotic with a unique structure. J. Antibiot. 25:685-688.[Medline]
    27. 27
  27. Uehara, Y. M., S. Hori, M. Kondo, M. Hamada, and H. Umezawa. 1976. Structure-activity relationships among negamycin analogs J. Antibiot. 29:937-943.[Medline]
    28. 28
  28. Vazquez, D. 1979. Inhibitors of protein biosynthesis. Springer-Verlag, Berlin, Germany.

Antimicrobial Agents and Chemotherapy, December 2007, p. 4462-4465, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00455-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schroeder, S. J.
Right arrow Articles by Moore, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schroeder, S. J.
Right arrow Articles by Moore, P. B.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»